Ryvu Therapeutics Eget kapital 2024

Vad gör Ryvu Therapeutics?

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.